Eye Diseases Clinical Trial
— INSIGHTOfficial title:
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Verified date | December 2022 |
Source | ProQR Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.
Status | Terminated |
Enrollment | 9 |
Est. completion date | October 3, 2022 |
Est. primary completion date | October 3, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility | Inclusion Criteria: - Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor - Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT. - Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator. - An adult (= 18 years) willing and able to provide informed consent for participation OR a minor (6 to < 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation. - Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol. Exclusion Criteria: - Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014). - Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor. - Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor. - Pregnant or breast-feeding female. |
Country | Name | City | State |
---|---|---|---|
Belgium | Ghent University Hospital and Ghent University | Ghent | |
United States | University of Iowa | Iowa City | Iowa |
United States | Scheie Eye Institute, University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
ProQR Therapeutics |
United States, Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of Ocular AEs | Frequency of ocular adverse events (AEs) | 24 months | |
Primary | Frequency of Non-ocular AEs | Frequency of non-ocular AEs | 24 months | |
Secondary | Change in BCVA in First Treated Eye | Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye | 24 months | |
Secondary | Change in Mobility Course Score | Change in Mobility course score | 24 months | |
Secondary | Change in Photoreceptor Outer Segment Layer Thickness | Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT) | 24 months | |
Secondary | Change in OCI | Change in Oculomotor Instability (OCI) | 24 months | |
Secondary | Change in FST Blue | Change in Full-Field Stimulus Testing (FST) - blue stimuli | 24 months | |
Secondary | Change in FST Red | Change in Full-Field Stimulus Testing (FST) - red stimuli | 24 months | |
Secondary | Change in VFQ-25 | Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects) | 24 months | |
Secondary | Change in CVAQ | Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects) | 24 months | |
Secondary | Change in PLR | Change in Pupillary Light Reflex (PLR) (latency and amplitude) | 24 months | |
Secondary | Change in NIRAF | Change in Near Infrared AutoFluorescence (NIRAF) | 24 months | |
Secondary | Change in BCVA in Treated Contralateral Eye | Change in Best Corrected Visual Acuity (BCVA) in Treated Contralateral Eye | 24 months | |
Secondary | Change in BCVA in Non-Treated Contralateral Eye | Change in Best Corrected Visual Acuity (BCVA) in Non-Treated Contralateral Eye | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|